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ABSTRACT
Objective: Nateglinide (NTG) is a potent short-acting biopharmaceutical classification system class II antidiabetic medication. The primary objective 
of the present investigation was to prepare and evaluate solid dispersions of NTG to enhance the component solubility and immediate release (IR) 
profile. The secondary objective was to formulate sustained release (SR) matrix layer of NTG for prolonging its effect in the body and to decrease 
oscillations in plasma concentration level.
Methods: NTG (270 mg) SR layer was formulated using release retardant polymers such as Carbopol, ethyl cellulose (EC), hydroxy EC, hydroxypropyl 
methylcellulose (HPMC), Kollidon, and locust bean gum at concentrations of 15% and 30%. IR layer of NTG (60 mg) was formulated using drug: 
Polymer inclusion complexes (1:1 and 1:2) of β-cyclodextrin (CD), HP β-CD, polyvinylpyrrolidone (PVP) K-15, and PVP K-30 by physical mixing and 
kneading methods (KMs).
Results: Among the all the carriers tested HP β-CD at 1:2 ratio prepared by KM (I3) gave highest enhancement of dissolution rate and dissolution 
efficiency with acceptable f1 (10.5) and f2 (51.0) values in comparison to marketed IR tablets (Starlix-60®). The SR formulation S12 was able to show 
a minimum amount of drug release (15%) within 1 hr comparatively, with a complete and sustained effect on drug release.
Conclusion: Thus, HPMC K-100M at a concentration of 30% in the SR layer in combination with HP β-CD (1:2) solid dispersions in the IR layer may 
be used in the design of oral controlled drug delivery system for NTG.
Keywords: Controlled release, Diabetes mellitus, Dissolution, Meglitinides, Solid dispersion, Solubility.
INTRODUCTION
Diabetes is a chronic condition associated with abnormally high levels 
of sugar (glucose) in the blood. Diabetes was the 7th leading cause of 
death in the United States listed on death certificates in 2007. The two 
types of diabetes are referred to as type 1 (juvenile-onset or insulin-
dependent diabetes) and type 2 (adult-onset or non-insulin-dependent 
diabetes mellitus [NIDDMs]). The major complications of diabetes 
are both acute and chronic. The major goal in treating diabetes is to 
minimize any elevation of blood sugar (glucose) without causing 
abnormally low levels of blood sugar. Type 1 diabetes is treated with 
insulin, exercise, and diabetic diet. Type 2 diabetes is first treated 
with weight reduction, a diabetic diet, and exercise [1]. When these 
measures fail to control the elevated blood sugars, oral medications are 
used. If oral medications are still insufficient, insulin medications and 
other injectable medications are considered [2].
Insulin produced by the pancreas lowers blood glucose. The absence 
or insufficient production of insulin causes diabetes. The class of 
drugs known as meglitinides is relatively new, which act by binding 
selectively to pancreatic β-cells to stimulate insulin release. Unlike the 
sulfonylureas that bind to receptors on the insulin-producing cells, 
meglitinides work through separate potassium-based channel on the 
cell surface. Meglitinides may have a neutral effect on weight or cause 
a slight increase in weight [3]. The average weight gain caused by 
meglitinides appears to be lower than that caused by sulfonylureas and 
insulin appears to occur only in those native to oral antidiabetic drugs. 
Meglitinides are also relatively safe to use in people with impaired 
kidney function. Due to their mechanism of action, meglitinides may 
cause hypoglycemia, but the literature suggests that the risk is lower 
than that caused by sulfonylureas and insulin since their action is 
dependent on the presence of glucose [4]. Meglitinides appear to be 
more effective at lowering post-prandial blood glucose than metformin, 
sulfonylureas, and thiazolidinediones [5].
Nateglinide (NTG) is an oral antihyperglycemic agent used for the 
treatment of NIDDM. NTG is an amino acid derivative belongs to the 
meglitinides class of short-acting insulin secretagogues. It potentiates 
the effect of extracellular glucose on adenosine triphosphate-sensitive 
potassium channel and has little effect on insulin between meals 
and overnight [6]. As such, NTG is more effective at reducing post-
prandial blood glucose levels and does not tend to lower fasting 
blood glucose levels to the same degree. Approximately one month of 
therapy is required before a decrease in fasting blood glucose is seen. 
The insulinotropic effects of NTG are highest at intermediate glucose 
levels (3-10 mmol/l) and it does not increase insulin release already 
stimulated by high glucose concentrations (>15 mmol/l). Unlike 
the sulfonylureas which last longer in the body, NTG (Starlix) is very 
short-acting (half-life~1.5 hr), with peak effects within one hour of 
oral administration [7,8]. For this reason, the immediate release (IR) 
tablets of NTG has been commercialized as an antidiabetic agent for the 
treatment of type 2 diabetics, and it is required to be administered at a 
dose of 60/120 mg twice or thrice a day just before meals. The major 
benefit of NTG is that the starting dose of 120 mg does not need to be 
adjusted upward, but rather remains constant. Therefore, to prolong its 
effect in the body and to decrease oscillations in concentration level in 
plasma. A modified drug delivery system is needed for NTG to improve 
solubility, dissolution rate, and patient compliance, and to decrease 
the side effects [9,10]. NTG is practically insoluble in water and has an 
absolute bioavailability of approximately 73%. Hence, it is desirable 
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to enhance the solubility and dissolution profile of NTG using various 
cyclodextrins (CD)/polyvinyl pyrrolidone (PVP) in combination with 
release retardant polymers such as ethyl cellulose (EC), hydroxyl EC 
(HEC), hydroxypropyl methylcellulose (HPMC), Carbopol, Kollidon, and 
various natural gums [11,12].
NTG undergoes extensive first-pass metabolism by hydroxylation 
followed by glucuronide conjugation. The major metabolites possess 
less activity than the parent compound. One major metabolite, the 
isoprene, has the same potency as its parent compound. NTG is 
approximately 98% bound to proteins (primarily albumin and to 
a lesser extent to alpha-L acid glycoprotein). Multiparticulate drug 
delivery systems have considerable potential for the treatment of 
chronic diseases such as diabetes [13,14]. The important technological 
advantages of solid dispersions used as drug carriers are high stability, 
high carrier capacity, feasibility of incorporation of both hydrophilic 
and hydrophobic substances, and feasibility of variable routes of 
administration including oral application and inhalation. These 
properties of solid dispersions enable improvement of drug solubility, 
dissolution rate, bioavailability, and may resolve the problem of patient 
incompliance [15]. The proposed research studies were carried out 
on the enhancement of dissolution rate of NTG by solid dispersion 
technology employing various water dispersible carriers.
For the improvement of compliance to patients, however, it is desired 
to develop an SR oral dosage form instead of IR tablet. NTG belongs 
to biopharmaceutical classification system Class II, that is, why we 
can develop a solubility/dissolution enhanced form of it using various 
techniques such as solid dispersion [16-21]. Because NTG is having 
low t1/2, which is unable to reach the therapeutic concentration, CR 
formulations are designed. The release of NTG should be sustained 
as its therapeutic absorption window is in the intestine. The value of 
hydrophilic, polymer-based matrix system as carriers for controlled 
drug delivery is well recognized and increasingly demonstrated by 
the numerous patents, research papers, and the US food and drug 
administration approved matrix-based products [22]. In particular, 
water soluble cellulose ethers (e.g., HPMC, HPC, HEC, EC), PEO, Kollidon, 
Carbopol, and polysaccharides such as locust bean gum (LBG) have 
been extensively used [23].
When we are combining both the technologies, we can enhance the 
efficacy of drug as well as we can maintain the drug concentration 
in plasma such that it maintains in therapeutic concentration for the 
desired time [24]. The present research endeavor was thus directed 
toward the development of safe and effective controlled-release dosage 
form of NTG to be taken once daily to maintain the optimum therapeutic 
levels over an extended period, reducing the price of drug, and making 
the drug more affordable to the patients [25,26]. The prepared bilayer 
tablets prepared using the optimized formula of the IR layer (60 mg of 
NTG) and optimized formula of sustained release (SR) (270 mg of NTG) 
matrix system were evaluated for pre-compression parameters, weight 
variation, hardness, friability, drug content, in vitro drug release, and 
kinetic studies in comparison with marketed product (Starlix®).
MATERIALS AND METHODS
Materials
NTG was gift samples from Glenmark Pharmaceutical Ltd., Pune. EC, 
hydroxypropyl cellulose (HPC), hydroxy EC (HEC), β-CD, and HP β-CD 
(HP β-CD) were obtained from Signet chemicals, Mumbai. HPMC K-100 
was procured from Colorcon, Goa. Kollidon SR, polyvinylpyrrolidone 
(PVP) K-17, and polyvinylpyrrolidone K-30, microcrystalline cellulose 
(MCC), sodium starch glycolate (SSG) were obtained from S.D. fine-
chem. Ltd., Mumbai. LBG, Carbopol 971 P, Dicalcium phosphate (DCP), 
magnesium stearate, and colloidal silica were procured from Lubrizol 
Pvt. Ltd., Mumbai. All other chemicals and solvents used were of 
analytical grade. The commercial brand of IR tablet: Starlix® containing 
60 mg of NTG (batch No. A2026SU, Novartis) was used for comparison 
of optimized solid dispersion in the present study.
Pre-formulation studies
Standard plot of NTG
NTG exhibits peak absorbance at 212 nm in 0.01 N hydrochloric acid 
(HCl) (pH 2) and pH 6.8 phosphate buffer containing 0.5% sodium 
lauryl sulfate (SLS). The concentration of NTG was found to be linear in 
range of 0-10 µg/ml with a correlation coefficient of r=0.999. The linear 
regression equation was found to be y=0.031x+0.002, which can be 
used for estimation of NTG drug concentration in 0.01 N HCl containing 
0.5% SLS. NTG has shown linear relationship in the range of 0-10 µg/ml 
in pH 6.8 phosphate buffer containing 0.5% SLS, and the regression 
equation was found to be y=0.024x−0.002 with a correlation coefficient 
(r) of 0.998, which can be used for the estimation of drug concentration.
Solubility studies
The solubility of NTG was determined by adding excess but measured 
amount (20 mg) of drug in 25 ml volumetric flask containing 0.01 N HCl 
with 0.5% SLS and kept in rotary shaker for 24 hrs at room temperature. 
The dispersions were filtered through Whatman filter paper (No.1) and 
analyzed for the quantity of drug dissolved by taking the absorbance 
and was determined from their respective standard plots.
Drug-excipient compatibility studies
Fourier transform infrared (FTIR) spectroscopy analysis was performed 
to pure drug (NTG), physical mixtures of drug with β-CD (1:1), HP 
β-CD (1:1), PVP K-17 (1:1) physical mixing (PM), PVP K-30 (1:1) PM, 
PVP K-17 (1:1) kneading method (KM), PVP K-30 (1:1) KM, and final 
optimized formulation. The IR absorption spectra of the pure drug with 
different excipients were taken in the range of 4000-450 cm−1 using 
KBr disc method. Around 1-2 mg of the substance to be examined was 
triturated with 300-400 mg of finely powdered and dried potassium 
bromide. These quantities are usually sufficient to give a disc of 
10-15 mm diameter and pellet of suitable intensity by a hydraulic press. 
Each spectrum was derived from 16 single average scans collected 
under identical conditions at a spectral resolution of 2cm−1.
Preparation of solid dispersions
Solubility determination
Solubility studies were performed in triplicate according to the Higuchi 
and Connors method. To improve solubility and dissolution rate of 
NTG, complexation with β-CD, HP β-CD, PVP K-17, and PVP K-30 were 
prepared at different concentrations [27]. Sixteen formulations of NTG 
solid dispersions were prepared by two different methods, namely, PM 
and KM.
Analysis of prepared solid dispersions
The formulations prepared were subjected to pre-compression 
parameters and physicochemical properties evaluation. In vitro 
dissolution studies were performed for two hours using USP dissolution 
rate test apparatus II in 0.01 N HCl containing 0.5% SLS at 50 rpm 
and 37±0.5°C [28]. The amount of NTG released from the SR tablet 
formulations was estimated at 212 nm using a UV spectrophotometer.
Preparation of IR layer
Formulation of IR layer was done by taking pure drug NTG 60 mg 
(loading dose) labeled as formulation I1 of total weight 400 mg. 
Formulations I2, I3, I4, and I5 were prepared by employing drug: 
Inclusion complexes in the ratio 1:2 β-CD and HP β-CD by PM and KMs 
with SSG and MCC as superdisintegrant and diluent, respectively. All 
the formulated IR tablets employing solid dispersions exhibited rapid 
and higher drug dissolution when compared to tablets formulated with 
pure drug (F1) and also commercial tablets of NTG (Starlix®).
Preparation of SR layer
Formulation trials were done using the six-stated polymers by wet 
granulation method. The SR tablet of 470 mg containing 270 mg 
(maintenance dose) of NTG was prepared using various controlled-
release polymers, namely, cellulose derivatives such as EC, HEC, HPMC, 
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Kollidon to enhance the aqueous solubility of the drug; saccharide 
derivatives such as LBG; and acrylate derivatives such as Carbopol. In 
the present SR matrix formulation, DCP was used as filler to impart 
physical stability to the drug; colloidal silica and magnesium stearate 
were used as glidant and lubricant, respectively, to improve the flow 
properties; povidone was used as a binder and purified water as a 
solvent for the binder.
Twelve formulations were prepared by varying the concentration 
of six polymers at two levels of 15% and 30%. The formulations 
prepared were subjected to evaluation of pre-compression parameters 
and physicochemical properties. In vitro dissolution studies were 
conducted for 12 hrs using USP dissolution rate test apparatus II in 
0.01 N HCl containing 0.5% SLS for 2 hrs followed by pH 6.8 phosphate 
buffer at 50 rpm and 37±0.5°C. The amount of NTG released from 
the SR tablet formulations was estimated at 212 nm using a UV 
spectrophotometer.
Preparation of bilayer tablet
All the ingredients were passed through 100 mesh sieve separately. 
Weighed quantity of NTG and all other excipients except lubricant 
and glidant were taken in mortar and prepared the wet mass using 
PVP K-30 binder solution in ethanol. This wet mass was passed 
through 60 mesh sieve and dried in hot air oven at 50°C up to 
optimum drying. Dried granules were passed through 100 mesh 
sieve. Magnesium stearate and AEROSIL were added to these dried 
granules. Later, these were subjected for punching using RIMEK multi 
station tablet punching machine using round flat surface punches 
of 12 mm diameter. After compression of the SR layer, the upper 
punch was lifted, and the optimized blend of powder for IR layer 
(containing 60 mg NTG) was poured into the die cavity, containing 
initially compressed SR matrix tablet (containing 270 mg NTG). This 
bilayer tablet compression was performed by RIMEK multi station 
punching machine using flat punches. The details of the composition 
of the IR (I1-I5) and SR (S1-S12) layer of bilayer tablet are given in 
Table 1.
Analysis of IR and SR formulations of bilayer tablet
Evaluation of pre-compression parameters of prepared 
formulations
The blend of all the prepared formulations was evaluated for their flow 
properties before compression by characterization of bulk density, 
tapped density, compressibility index, Hausner’s ratio, and angle of 
repose.
Evaluation of post-compression parameters of prepared 
formulations
The weight variation, hardness, thickness, and friability of the tablets 
were measured in electronic balance (Shimadzu, Mumbai), hardness 
tester (Pfizer, Mumbai), digital caliper (Vernier, Mumbai) and friabilator 
(Electrolab, Mumbai), respectively.
Estimation of drug content in tablets
An accurately weighed quantity (10 mg and 45 mg) of powdered 
IR and SR tablet was transferred separately to a 100 mL volumetric 
flask, and the NTG was extracted into 50 mL of methanol. The volume 
is made up to 100 mL with 0.01 N HCl containing 0.05% SLS for 
IR and pH 6.8 phosphate buffer for SR formulation [29]. The stock 
solutions were filtered and suitably diluted with the corresponding 
solvent. The drug content was assayed using double-beam UV-Visible 
spectrophotometer (model SL210, Elico, Hyderabad), in a 1 cm quartz 
cell, at 212 nm in both IR and SR formulations. Each drug content 
estimation procedure was replicated six times.
In vitro dissolution rate studies
In vitro dissolution studies of IR formulations
Dissolution of the tablets was carried out on USP XXIII dissolution 
type I apparatus (Model No. TDT-08L, Electrolab, Mumbai). The tablet 
was fixed to the paddle by hydration mechanism. The dissolution vessel 
was filled with 900 ml of 0.01 N HCl containing 0.5% SLS (pH 2.0) 
and the temperature of the dissolution medium was maintained at 
37±0.5°C. The rotational speed of the paddle was set at 50 rpm. At 
suitable intervals, 5 ml of sample was withdrawn and same volume 
of fresh medium was replaced. The withdrawn samples were filtered, 
diluted when necessary with the dissolution medium, and analyzed 
spectrophotometrically at 212 nm using 0.01 N HCl containing 0.5% 
SLS as blank. The mean cumulative percentage drug release was 
calculated and plotted against time.
In vitro dissolution studies of bilayer tablets
Dissolution of the tablets was carried out on USP XXIII dissolution 
type I apparatus (Model No. TDT-08L, Electrolab, Mumbai). The tablet 
was fixed to the paddle by hydration mechanism. The dissolution vessel 
was filled with 900 ml of 0.01 N HCl containing 0.5% SLS (pH 2.0) for 
first two hours and thereafter replaced with pH 6.8 phosphate buffer 
for the remaining 10 hrs. The temperature of the dissolution medium 
was maintained at 37±0.5°C with paddle rotational speed of 50 rpm. 
At suitable intervals, 5 ml of sample was withdrawn, and the same 
Table 1: Formulation details of immediate and SR layer of bilayer tablet
Ingredients (mg/tab) I1 I2 I3 I4 I5 S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12
NTG 60 - - - - 270 270 270 270 270 270 270 270 270 270 270 270
Drug: β-CD 1:2 (KM) - 172 - - - - - - - - - - - - - - -
Drug: HP β-CD 1: 2 (KM) - - 200 - - - - - - - - - - - - - -
Drug: β-CD 1:2 (PM) - - - 180 - - - - - - - - - - - - -
Drug: HP β-CD 1: 2 (PM) - - - - 180 - - - - - - - - - - - -
SSG 20 20 20 20 20 - - - - - - - - - - - -
MCC 312 200 172 192 192 - - - - - - - - - - - -
Kollidon SR - - - - - 67.5 135 - - - - - - - - - -
Carbopol 971P - - - - - - - 67.5 135 - - - - - - - -
EC - - - - - - - - - 67.5 135 - - - - - -
HEC - - - - - - - - - - - 67.5 135 - - - -
LBG - - - - - - - - - - - - - 67.5 135 - -
HPMC K-100 - - - - - - - - - - - - - - - 67.5 135
DCP - - - - - 86.5 86.5 86.5 86.5 86.5 86.5 86.5 86.5 86.5 86.5 86.5 86.5
PVP K-30 - - - - - 22 22 22 22 22 22 22 22 22 22 22 22
Colloidal silica 4 4 4 4 4 2 2 2 2 2 2 2 2 2 2 2 2
Magnesium stearate 4 4 4 4 4 2 2 2 2 2 2 2 2 2 2 2 2
Total amount 400 400 400 400 400 450 450 450 450 450 450 450 450 450 450 450 450
NTG: Nateglinide, HP: Hydroxypropyl, SR: Sustained release, SSG: Sodium starch glycolate, MCC: Microcrystalline cellulose, β-CD: β-Cyclodextrin, EC: Ethyl cellulose, 
HEC: Hydroxylethyl cellulose, LBG: Locust bean gum, HPMC: Hydroxypropyl methylcellulose, DCP: Dicalcium phosphate, PVP: Polyvinylpyrrolidone, KM: Kneading 
method, PM: Physical mixing
234
Asian J Pharm Clin Res, Vol 10, Issue 11, 2017, 231-238
 Boddu et al. 
volume of fresh medium was replaced. The withdrawn samples were 
filtered, diluted when necessary with the dissolution medium, and 
analyzed spectrophotometrically at 212 nm for NTG content. The mean 
cumulative percentage drug release was calculated and plotted against 
time. During the drug release studies, all the formulations were checked 
at intervals for their physical integrity.
Drug release kinetics
The release rate kinetics and mechanism of drug release from the 
IR and SR formulations were analyzed by fitting the data obtained 
into zero- and first-order models using PCPDISSO v2 software [30]. 
Based on the correlation coefficient (r) value, the best-fit model was 
selected.
The Korsmeyer-Peppas equation was used to analyze the data obtained 
from the in vitro release studies to evaluate the kinetic models and 
release mechanism of NTG from the SR matrices [31].
Comparison of optimized IR formulation with marketed product
Optimized IR formulation was compared with marketed IR tablets 
(Starlix®) containing 60 mg of NTG. The in vitro drug release profile of 
the optimized formulations (test) was compared with the theoretical 
release profile (reference) of marketed tablets by determining the 





The drug NTG has shown highest solubility in pH 6.8 phosphate buffer 
(1.61 mg/ml), followed by 0.01 N HCl containing 0.5% SLS (0.61 mg/
ml) and the least in distilled water (0.36 mg/ml) [33]. NTG is an acidic 
drug with one ionizable group (pKa=3.1)+ [34]. Hence, it requires 
enhancement of solubility to increase the bioavailability of the drug in 
the management of type 2 diabetes mellitus.
Drug-excipient interaction studies
From the FTIR data observed in Fig. 1, it was concluded that there were 
no considerable changes even after the development of tablet with 
references to the respective spectrums. The FTIR spectrum of NTG shown 
a characteristic peak at 3424.41 cm−1 due to COOH–O–H stretching, peak 
at 3315.91 cm−1 was observed due to N–H stretching of the secondary 
amide. The peaks at wave numbers 2924.74 and 2854.45 cm−1 were 
correspondence to CH3–C–H stretching, respectively. The COOH–C=O 
stretch at 1713.72 cm−1 and the secondary amide C=O stretching at 
1649.45 cm−1 were observed. All characteristic peaks obtained in the 
pure drug spectra were observed in physical mixture with minor shifts 
indicating there is no significant interaction between the drug (NTG) 
and the excipients which were employed in the present study.
Fig. 1: Fourier transform infrared spectras of (a) NTG, (b) NTG: β-CD, (c) NTG: HP β-CD, (d) NTG: PVP K-17, (e) NTG: PVP K-30, and 
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Solid dispersions
Solubility determination
The effect of four different carriers, that is, β-CD, HP β-CD, PVP K-17, 
and PVP K-30 on the solubility and dissolution rate of NTG was studied 
at different concentrations [35]. At 1% w/v of HP β-CD, NTG had shown 
the highest solubility of 97.5% as shown in Fig. 2.
The solubility of NTG was increased as the concentration of carrier was 
increased in the solid dispersions due to the formation of inclusion 
complexes. The solubility of NTG was 40% at zero percent carrier 
concentration and increases to around 90% at one percent carrier 
concentration of β-CD, PVP K-17, and PVP K-30. The solubility of NTG 
was increased up to 98% at one percent concentration of HP β-CD, 
indicating the formation of soluble inclusion complex between NTG 
and carrier.
Analysis of prepared solid dispersions
All the solid dispersions prepared were found to be fine free-flowing 
powders. The drug content was uniform in all the solid dispersion 
batches. The dissolution of NTG from all the solid dispersions was rapid 
and several times higher than the dissolution of the corresponding pure 
drug as shown in Table 2.
Drug dissolution from all solid dispersions followed first-order kinetics. 
All the dissolution parameters estimated, that is, T50, T90, DE30%, and K1 
values indicated rapid and higher dissolution of the drug (NTG) from 
solid dispersions than that of corresponding pure drug. The dissolution 
rate of nateglinide with various carriers is in the order of: HPβ-CD>β-
CD>PVPK17>PVP K30. In each case, the dissolution rate (K1) and 
DE30% were increased as the concentration of carriers in the solid 
dispersions was increased.
For solid dispersions prepared with β-CD, a 1.9- and 2.3-fold increase 
in dissolution rate (K1) and DE30%, respectively, was observed with 1:1 
ratio of physical mixture. A 2.85- and 3.36-fold increase in dissolution 
rate (K1) and DE30%, respectively, was observed with 1:1 ratio of KM. 
A 2.38- and 2.52-fold increase in dissolution rate (K1) and DE30%, 
respectively, was observed with 1:2 ratio of physical mixture. A 3.8- and 
3.49-fold increase in dissolution rate (K1) and DE30%, respectively, was 
observed with 1:2 ratio of KM. In case of solid dispersions prepared 
with HP β-CD, a 2.38- and 2.61-fold increase in dissolution rate (K1) and 
DE30%, respectively, was observed with 1:1 ratio of physical mixture. 
A 4.76- and 3.42-fold increase in dissolution rate (K1) and DE30%, 
respectively, was observed with 1:1 ratio of KM. A 3.36- and 2.77-fold 
increase in dissolution rate (K1) and DE30%, respectively, was observed 
with 1:2 ratio of physical mixture. A 6.66- and 3.55-fold increase in 
dissolution rate (K1) and DE30%, respectively, was observed with 1:2 
ratio of KM.
Whereas for solid dispersions prepared with PVP K-17, a 2.38- and 
2.35-fold increase in dissolution rate (K1) and DE30%, respectively, 
was observed with 1:1 ratio of physical mixture. A 2.85- and 2.82-fold 
increase in dissolution rate (K1) and DE30%, respectively, was observed 
with 1:1 ratio of KM. A 2.85- and 2.43-fold increase in dissolution rate 
(K1) and DE30%, respectively, was observed with 1:2 ratio of physical 
mixture. A 4.28- and 2.89-fold increase in dissolution rate (K1) and 
DE30%, respectively, was observed with 1:2 ratio of KM. While that 
of solid dispersions prepared with PVP K-30, a 1.90- and 2.51-fold 
increase in dissolution rate (K1) and DE30%, respectively, was observed 
with 1:1 ratio of physical mixture. A 2.38- and 2.53-fold increase in 
dissolution rate (K1) and DE30%, respectively, was observed with 1:1 
ratio of KM. A 1.90- and 2.66-fold increase in dissolution rate (K1) and 
DE30%, respectively, was observed with 1:2 ratio of physical mixture. 
A 2.85- and 2.84-fold increase in dissolution rate (K1) and DE30%, 
respectively, was observed with 1:2 ratio of KM.
From Fig. 3, it is clear that when compared to pure drug NTG, drug 
inclusion complexes prepared with different CDs (β-CD, HP β-CD) by 
PM and KM gave the maximum solubility and dissolution rate of drug 
from prepared solid dispersions. Hence, inclusion complexes of NTG 
with β CD and HP β CD in the ratio of 1:2 (drug:polymer) were further 
optimized by preparing IR layer of NTG.
IR formulation
Analysis of prepared IR formulations
All the pre-compression parameters such as angle of repose (<25°), 
compressibility index (15.05-20.02%), and Hausner’s ratio (<1.25) 
were within the limits of official standards displaying good flow 
properties of the prepared granules (I1-I5).
All post-compression parameters such as weight variation, hardness, 
thickness, friability, disintegration time, and drug content were found 
to be within the limits of official standards. The weight variation for a 
tablet weighing around 400 mg was found to be with in official limits 
of NMT 5%. The measured hardness of the tablets of each batch of 
all formulations, that is, I1-I5 was between 3 and 3.5 kg/cm2 and 
optimum for an IR formulation. The percent friability of formulated 
tablets was found to be <1% ensuring that IR layer was mechanically 
stable. The thickness of the tablets was found to be almost uniform 
in all formulations I1-I5 in the range of 2.0-2.2 mm with less % RSD. 
The drug content of each batch formulations (I1-I5) was evaluated 
as per the standard protocol, and the percentage of drug content was 
found to be 98.2-99.4%. The disintegration time of all the prepared IR 
formulations was <30 seconds, with a least disintegration time of 24 sec 
from formulation I3 prepared with HP β-CD drug complex (1:2) by KM.
Fig. 2: Solubility plot of nateglinide using different carriers (n=3, 
mean±standard deviation)
Table 2: Estimated dissolution parameters of NTG solid 
dispersions
S. No. T50 (minutes) T90 (minutes) DE 30% K1
β-CD 1:1 (PM) 30 >120 53.73 0.008
β-CD 1:1 (KM) 13 >120 59.05 0.012
β-CD 1:2 (PM) 16 >120 78.55 0.010
β-CD 1:2 (KM) 10 90 81.51 0.016
HP β-CD 1:1 (PM) 15 >120 61.11 0.010
HP β-CD 1:1 (KM) 11 95 64.86 0.020
HP β-CD 1:2 (PM) 12 110 80.10 0.014
HP β-CD 1:2 (KM) 6 55 83.11 0.028
PVP K-17 1:1 (PM) 35 >120 55.20 0.010
PVP K-17 1:1 (KM) 22 >120 56.81 0.012
PVP K-17 1:2 (PM) 27 >120 65.87 0.012
PVP K-17 1:2 (KM) 15 98 67.71 0.018
PVP K-30 1:1 (PM) 45 >120 58.8 0.008
PVP K-30 1:1 (KM) 38 >120 62.23 0.010
PVP K-30 1:2 (PM) 40 >120 59.10 0.008
PVP K-30 1:2 (KM) 30 >120 57.73 0.012
NTG: Nateglinide, HP: Hydroxypropyl, β-CD: β-Cyclodextrin, 
PVP: Polyvinylpyrrolidone, KM: Kneading method, PM: Physical mixing
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In vitro dissolution studies
All the formulated IR tablets employing solid dispersions exhibited 
rapid and higher drug dissolution when compared to formulation 
prepared with pure drug (I1) and commercial tablets of NTG (Starlix®). 
The dissolution rate of the five formulations were in the order of 
F3>F5>F2>F4>F1 as shown in Fig. 4. Among all the carriers tested, HP 
β-CD in the ratio of 1:2 prepared by KM gave the highest enhancement 
of dissolution rate and dissolution efficiency of NTG. The predicted 
responses for the optimized model for NTG IR layer (I3) were found to 
be 5 minutes, 100% drug release, and 43 minutes for T30, DR60, and 
T90, respectively.
The prepared formulations I1-I5 followed first-order kinetics with a 
higher correlation coefficient (r) values for Higuchi plot indicating the 
drug release occurs through diffusion mechanism. This was further 
confirmed by Korsmeyer-Peppas “n” values lying within 0.66-0.80, 
exhibiting non-Fickian diffusion mechanism of drug release.
Comparison of optimized IR formulation with marketed product
The dissolution rate and dissolution efficiency DE30% of I3 were 
greater than marketed formulation of NTG (Starlix®) as shown in 
Fig. 4. In the case of F2 formulation, a 6.89- and 1.29-fold increase 
in dissolution rate (K1) and DE30%, respectively, was observed. For 
F3 formulation, a 17.2- and 1.67-fold increase in dissolution rate 
(K1) and DE30%, respectively, was observed. For F4 formulation, 
a 5.51- and 1.35-fold increase in dissolution rate (K1) and DE30%, 
respectively, was observed. For F5 formulation, a 9.31- and 1.45-
fold increase in dissolution rate (K1) and DE30%, respectively, was 
observed.
In the case of marketed formulation (Starlix®), an 11.7- and 1.45-fold 
increase in dissolution rate (K1) and DE30%, respectively, was observed. 
The observed responses for the NTG-marketed IR tablets (Starlix®) 
were found to be 5 minutes, 92% drug release and 48 minutes for T30, 
DR60, and T90, respectively. Similarity factor (f1) and dissimilarity 
factor (f2) values of the matrix tablet were below 15 (10.5) and above 
50 (51.0), respectively, indicated similarities between the optimized 
formulation (I3) and theoretical release profiles.
SR formulation
As NTG is having low t1/2, which is unable to reach the therapeutic 
concentration, CR formulations are designed. The release of NTG should 
be sustained as its therapeutic absorption window is in the intestine.
Evaluation of pre-compression parameters
The prepared granules were evaluated for pre-compression parameters 
such as bulk density, tapped density, compressibility index, and 
Hausner’s ratio before being punched into tablets. The angle of repose 
of the formulations S1-S12 was found to be below 35° indicating 
excellent flow properties of the formulation. The compressibility index 
of formulations S1, S8, S11, and S12 were found to be in the range of 
12.00-14.60%, indicating the free flow, while the formulations S2, S3, 
S4, S5, S6, S7, S9, and S10 compressibility index was in the range of 
18.00-28%, indicating poor flow properties. The Hausner’s ratio of 
the formulations S1-S12, except S2 and S4 was <1.25 indicating good 
flowability.
Evaluation of post-compression parameters
The formulated tablets were evaluated for post-compression parameters 
such as weight variation, thickness, hardness, diameter, friability, and 
content uniformity. The weight variation for a tablet weighing around 
450 mg was found to be with in official limits of NMT 5%. The measured 
hardness of the tablets of each batch of all formulations, that is, S1-S12 
was between 5 and 6.5 kg/cm2, optimum for an SR formulation. The 
percent friability of formulated tablets was found to be <1% ensuring 
that SR layer was mechanically stable. The thickness of the tablets was 
found to be almost uniform in all formulations S1-S12 in the range of 
3.1-3.3 mm with less percentage RSD. The drug content of each batch 
formulations (S1-S12) was evaluated as per the standard protocol, 
and the percentage of drug content was found to be 97.00-99.33%. 
Hence, it is concluded that all the formulations are following the official 
acceptable limits of NTG.
In vitro dissolution studies
From the results of the in vitro dissolution profiles of the SR 
matrix formulations (Fig. 5), it can be observed that the rate of 
release retardant power of the six polymers taken was in the 
order of Carbopol 971P>EC>Kollidon SR>LBG>HPMC>HEC. The 
formulations S7, S9, and S12 prepared with HEC (1:1), LBG (1:1), 
and HPMC K-100 (1:2) as release controlling polymer has shown 
a drug release of 88%, 83%, and 80%, respectively, at the end of 
12 hrs. Among all formulations, S7, S9, and S12 exhibited the desired 
Fig. 4: In vitro drug release profile of nateglinide from prepared 
immediate release formulations I1-I5 and marketed tablets 
(Starlix®) (n=3, mean±standard deviation)
Fig. 3: In vitro dissolution profiles of nateglinide solid dispersions 
prepared with (a) β-CD and HP β-CD and (b) PVP K-17 and 
PVP K-30 (n=3, mean±standard deviation). CD: Cyclodextrin, 
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SR dissolution profiles with T50 values of 220 minutes, 240 minutes, 
and 430 minutes, respectively.
Drug release kinetics
The orders of kinetics and release mechanisms of all the prepared 
twelve SR formulations were determined using different mathematical 
model fittings. S7, S9 obeyed first-order release kinetics, whereas S12 
obeyed zero-order release kinetics following the anomalous release 
mechanism or non-Fickian diffusion. In Korsmeyer-Peppas equation, 
the “n” value of the formulations containing 15% and 30% of both the 
grades of HPMC was more than 0.5, whereas the “n” value was within 
0.5 in case of formulations containing 15% of HEC and LBG.
The release rate of the formulations that showed a par with the 
theoretical release rate (i.e., 7.8%/hrs) meant for once daily 
administration was selected for the 24 hrs in vitro study. The 
formulations S11 and S12 containing HPMC K-100M at 15% 
(k=7.6%/hrs) and 30% (k=7.9%) could retard the release of drug up 
to 24 hrs. The formulation S12 was able to show a minimum amount 
of drug release (15%) within 1 hr comparatively, with a complete and 
sustained effect on drug release.
CONCLUSION
Nateglinide is a quick acting anti-diabetic medication whose potent 
activity lasts for a short duration. The present investigation was 
aimed at developing a safe and effective controlled release dosage 
form of nateglinide for maintaining the optimum therapeutic levels 
over an extended period of time. The present work involves the 
optimization of solid dispersions of NTG to enhance the activity by 
improving component solubility and dissolution profile by forming 
inclusion complexes with CDs and comparing with marketed IR tablet 
(Starlix®-60 mg). SR matrix layer of NTG was formulated to prolong its 
effect in the body and to decrease oscillations in concentration level in 
plasma, being beneficial over conventional IR formulations. The release 
rate of the formulations that showed a par with the theoretical release 
rate (i.e., 7.8%/hrs) meant for once daily administration was selected 
for the 24 hrs in vitro study. It can be concluded that the once a day 
controlled-release oral dosage form of NTG may be formulated with 
1:2 ratio of drug: HP β-CD inclusion complex in the IR layer (containing 
60 mg of NTG-loading dose) and 1:2 ratio of drug: HPMC K-100 in the 
SR matrix layer (containing 270 mg of NTG – maintenance dose). This 
optimized formulation improves patient compliance by providing 
as biphasic drug release pattern in a single dosage form and ensures 
better disease management when compared to conventional IR tablets.
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